GlassScriptPhysician profile
Terry Meriden
NPI 1467538231
$79,280.73
in general payments reported to CMS, 2019-2025
27 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $17K · 2021: $499 · 2022: $912 · 2023: $679 · 2024: $328 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32,777.12 | 2019-2023 | Wegovy |
| Abbvie INC. | $14,452.93 | 2019-2020 | |
| Amarin Pharma, INC. | $9,333.79 | 2019-2022 | |
| Dexcom, INC. | $8,927.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $7,783.35 | 2019-2020 | |
| Medtronic Minimed, INC. | $1,280.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,085.88 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $624.98 | 2019-2023 | |
| Amgen INC. | $476.15 | 2019-2020 | |
| Corcept Therapeutics | $438.59 | 2019-2025 | Korlym |
| Abbott Laboratories | $340.69 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Regeneron Pharmaceuticals, INC. | $243.95 | 2019 | |
| Ascensia Diabetes Care US INC. | $218.57 | 2023-2024 | |
| Lilly USA, LLC | $192.15 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.02 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.27 | 2019-2020 | |
| Aytu Biopharma, INC. | $135.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.28 | 2021 | |
| Chiesi USA, INC. | $93.99 | 2024 | Mycapssa |
| Becton, Dickinson and Company | $91.89 | 2019 | |
| Insulet Corporation | $80.94 | 2019-2020 | |
| Medtronic, INC. | $78.05 | 2025 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $77.29 | 2019 | |
| Shire North American Group INC | $48.44 | 2019 | |
| Janssen Scientific Affairs, LLC | $45.84 | 2019 | |
| Valeritas, INC. | $18.77 | 2019 | |
| Currax Pharmaceuticals LLC | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Meriden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.